AstraZeneca is investing $2 billion in Summit Therapeutics, taking a potential 12% stake and partnering on cancer-drug development, including ivonescimab, while investors await upcoming FDA regulatory decisions.
Summit stock surges on $2 billion AstraZeneca investment
Published ·
Keep reading
Related stories
